827 related articles for article (PubMed ID: 31921562)
41. The therapeutic potential of indole hybrids, dimers, and trimers against drug-resistant ESKAPE pathogens.
Qiongxian Y; Jun D; Zhenfeng Z; Tongyou L; Zhicong T; Zhenyou T
Arch Pharm (Weinheim); 2024 Jun; ():e2400295. PubMed ID: 38924571
[TBL] [Abstract][Full Text] [Related]
42. Antibiotic Consumption and Its Relationship with Bacterial Resistance Profiles in ESKAPE Pathogens in a Peruvian Hospital.
Pérez-Lazo G; Abarca-Salazar S; Lovón R; Rojas R; Ballena-López J; Morales-Moreno A; Flores-Paredes W; Arenas-Ramírez B; Illescas LR
Antibiotics (Basel); 2021 Oct; 10(10):. PubMed ID: 34680802
[TBL] [Abstract][Full Text] [Related]
43. Antibacterial activity of medicinal plants against ESKAPE: An update.
Bhatia P; Sharma A; George AJ; Anvitha D; Kumar P; Dwivedi VP; Chandra NS
Heliyon; 2021 Feb; 7(2):e06310. PubMed ID: 33718642
[TBL] [Abstract][Full Text] [Related]
44. CRISPR in Modulating Antibiotic Resistance of ESKAPE Pathogens.
Saha U; Gondi R; Patil A; Saroj SD
Mol Biotechnol; 2023 Jan; 65(1):1-16. PubMed ID: 35939207
[TBL] [Abstract][Full Text] [Related]
45. Preliminary survey of local bacteriophages with lytic activity against multi-drug resistant bacteria.
Latz S; Wahida A; Arif A; Häfner H; Hoß M; Ritter K; Horz HP
J Basic Microbiol; 2016 Oct; 56(10):1117-1123. PubMed ID: 27194637
[TBL] [Abstract][Full Text] [Related]
46. Escaping mechanisms of ESKAPE pathogens from antibiotics and their targeting by natural compounds.
Jadimurthy R; Mayegowda SB; Nayak SC; Mohan CD; Rangappa KS
Biotechnol Rep (Amst); 2022 Jun; 34():e00728. PubMed ID: 35686013
[TBL] [Abstract][Full Text] [Related]
47. A Whole-Cell Screen Identifies Small Bioactives That Synergize with Polymyxin and Exhibit Antimicrobial Activities against Multidrug-Resistant Bacteria.
Zimmerman SM; Lafontaine AJ; Herrera CM; Mclean AB; Trent MS
Antimicrob Agents Chemother; 2020 Feb; 64(3):. PubMed ID: 31844003
[TBL] [Abstract][Full Text] [Related]
48. Frequency and clinical outcomes of ESKAPE bacteremia in solid organ transplantation and the risk factors for mortality.
Ye QF; Zhao J; Wan QQ; Qiao BB; Zhou JD
Transpl Infect Dis; 2014 Oct; 16(5):767-74. PubMed ID: 25124187
[TBL] [Abstract][Full Text] [Related]
49. Interplay between ESKAPE Pathogens and Immunity in Skin Infections: An Overview of the Major Determinants of Virulence and Antibiotic Resistance.
Vale de Macedo GHR; Costa GDE; Oliveira ER; Damasceno GV; Mendonça JSP; Silva LDS; Chagas VL; Bazán JMN; Aliança ASDS; Miranda RCM; Zagmignan A; Monteiro AS; Nascimento da Silva LC
Pathogens; 2021 Feb; 10(2):. PubMed ID: 33540588
[TBL] [Abstract][Full Text] [Related]
50. Norfloxacin salts of carboxylic acids curtail planktonic and biofilm mode of growth in ESKAPE pathogens.
Lowrence RC; Ramakrishnan A; Sundaramoorthy NS; Shyam A; Mohan V; Subbarao HMV; Ulaganathan V; Raman T; Solomon A; Nagarajan S
J Appl Microbiol; 2018 Feb; 124(2):408-422. PubMed ID: 29178633
[TBL] [Abstract][Full Text] [Related]
51. Prevalence of Infections and Antimicrobial Resistance of ESKAPE Group Bacteria Isolated from Patients Admitted to the Intensive Care Unit of a County Emergency Hospital in Romania.
Bereanu AS; Bereanu R; Mohor C; Vintilă BI; Codru IR; Olteanu C; Sava M
Antibiotics (Basel); 2024 Apr; 13(5):. PubMed ID: 38786129
[TBL] [Abstract][Full Text] [Related]
52. Recent advances in the development of antimicrobial peptides against ESKAPE pathogens.
Roque-Borda CA; Primo LMDG; Franzyk H; Hansen PR; Pavan FR
Heliyon; 2024 Jun; 10(11):e31958. PubMed ID: 38868046
[TBL] [Abstract][Full Text] [Related]
53. Acinetobacter baumannii: Pathogenesis, virulence factors, novel therapeutic options and mechanisms of resistance to antimicrobial agents with emphasis on tigecycline.
Dehbanipour R; Ghalavand Z
J Clin Pharm Ther; 2022 Nov; 47(11):1875-1884. PubMed ID: 36200470
[TBL] [Abstract][Full Text] [Related]
54. Ventilator-associated pneumonia caused by ESKAPE organisms: cause, clinical features, and management.
Sandiumenge A; Rello J
Curr Opin Pulm Med; 2012 May; 18(3):187-93. PubMed ID: 22366995
[TBL] [Abstract][Full Text] [Related]
55. Characterization of Novel
Mulani MS; Kumkar SN; Pardesi KR
Microbiol Spectr; 2022 Dec; 10(6):e0199422. PubMed ID: 36374021
[TBL] [Abstract][Full Text] [Related]
56. Antimicrobial Activity of Two Different Types of Silver Nanoparticles against Wide Range of Pathogenic Bacteria.
Holubnycha V; Husak Y; Korniienko V; Bolshanina S; Tveresovska O; Myronov P; Holubnycha M; Butsyk A; Borén T; Banasiuk R; Ramanavicius A; Pogorielov M
Nanomaterials (Basel); 2024 Jan; 14(2):. PubMed ID: 38251102
[TBL] [Abstract][Full Text] [Related]
57. Liquid Extraction Surface Analysis Mass Spectrometry of ESKAPE Pathogens.
Havlikova J; May RC; Styles IB; Cooper HJ
J Am Soc Mass Spectrom; 2021 Jun; 32(6):1345-1351. PubMed ID: 33647207
[TBL] [Abstract][Full Text] [Related]
58. Mortality Predictors in Acute Respiratory Distress Syndrome Renal Transplant Recipients With ESKAPE/rESKAPE Pneumonia.
Chu L; Ye QF; Wan QQ; Zhou JD
Transplant Proc; 2015 Oct; 47(8):2450-5. PubMed ID: 26518949
[TBL] [Abstract][Full Text] [Related]
59. Gram-negative ESKAPE bacteria bloodstream infections in patients during the COVID-19 pandemic.
Alcántar-Curiel MD; Huerta-Cedeño M; Jarillo-Quijada MD; Gayosso-Vázquez C; Fernández-Vázquez JL; Hernández-Medel ML; Zavala-Pineda M; Morales-Gil MÁ; Hernández-Guzmán VA; Bolaños-Hernández MI; Giono-Cerezo S; Santos-Preciado JI
PeerJ; 2023; 11():e15007. PubMed ID: 37013147
[TBL] [Abstract][Full Text] [Related]
60. Emerging Strategies to Combat β-Lactamase Producing ESKAPE Pathogens.
Vrancianu CO; Gheorghe I; Dobre EG; Barbu IC; Cristian RE; Popa M; Lee SH; Limban C; Vlad IM; Chifiriuc MC
Int J Mol Sci; 2020 Nov; 21(22):. PubMed ID: 33198306
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]
